Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Lauren T. Adrian"'
Autor:
Brian J. Druker, Thomas O'Hare, Michael W.N. Deininger, Daniel L. Flynn, Peter A. Petillo, Bryan D. Smith, Scott C. Wise, David J. Anderson, Mary Mac Partlin, Jeffrey W. Tyner, Lauren T. Adrian, Christopher A. Eide
Supplementary Tables 1-4, Figure 1 from The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a2432ac3c84471ba506f96d9dd9a62f
https://doi.org/10.1158/0008-5472.22392068
https://doi.org/10.1158/0008-5472.22392068
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 1469K, Different ABL TKIs demonstrate potency differences in relative cellular and biochemical target inhibition (S1); Incomplete restoration of BCR-ABL signaling activity following washout of dasatinib or ponatinib tracks with intracellul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45bb2f349dbdbd12daa46b5865710272
https://doi.org/10.1158/0008-5472.22396247
https://doi.org/10.1158/0008-5472.22396247
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 337K, Summary of mean fluorescence intensity values for levels of CrkL and STAT5 phosphorylation in K562 cells following acute ABL TKI exposure followed by standard and expanded washout (S1); Kinase:inhibitor dissociation off-rates for ABL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464ff7a97c638799f3fd2f9fd2378704
https://doi.org/10.1158/0008-5472.22396238.v1
https://doi.org/10.1158/0008-5472.22396238.v1
Autor:
Brian J. Druker, Michael W. Deininger, Jeffrey W. Tyner, John Apgar, Dennis R. Koop, Kurt W. Vogel, Bryan D. Marks, Steven M. Riddle, Jenny Luo, Huihong You, Kara J. Johnson, Dorian H. LaTocha, Ryan J. MacKenzie, Matthew S. Zabriskie, Lauren T. Adrian, Anupriya Agarwal, Christopher A. Eide, Thomas O'Hare
PDF file - 45K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2e7b60dba00e64f41fe83e32b81c9f
https://doi.org/10.1158/0008-5472.22396250.v1
https://doi.org/10.1158/0008-5472.22396250.v1
Autor:
Bryan D. Smith, Jeffrey W. Tyner, Peter A. Petillo, Brian J. Druker, Lauren T. Adrian, Michael W. Deininger, Christopher A. Eide, Mary Mac Partlin, Daniel L. Flynn, Scott C. Wise, David J. Anderson, Thomas O'Hare
Publikováno v:
Cancer Research. 71:3189-3195
Acquired point mutations within the BCR-ABL kinase domain represent a common mechanism of resistance to ABL inhibitor therapy in patients with chronic myeloid leukemia (CML). The BCR-ABLT315I mutant is highly resistant to imatinib, nilotinib, and das
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021dda432b977dd6f4199c40a8d2530f
https://doi.org/10.1158/0008-5472.can-10-3224
https://doi.org/10.1158/0008-5472.can-10-3224
Autor:
Brian J. Druker, Amie S. Corbin, Yihan Wang, Yaoyu Ning, Huang Wei Sheng, Lois Commodore, Tomi K. Sawyer, Lauren T. Adrian, Xiaotian Zhu, Michael W. Deininger, David C. Dalgarno, Joseph Snodgrass, Jeffrey A. Keats, Raji Sundaramoorthi, William C. Shakespeare, Jeffrey W. Tyner, Christopher A. Eide, Thomas O'Hare, Marc M. Loriaux, Frank Wang, Scott Wardwell, Chester A. Metcalf, Dong Zhou, Victor M. Rivera, Qihong Xu, Mathew Thomas, Tim Clackson, Tianjun Zhou
Publikováno v:
Cancer Cell. 16:401-412
SummaryInhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b4afb0777bbae5edb9a221150450377
https://doi.org/10.1016/j.ccr.2009.09.028
https://doi.org/10.1016/j.ccr.2009.09.028
Autor:
Christopher A. Eide, Brian J. Druker, Thoralf Lange, Jennifer Snead, Michael W. Deininger, Lauren T. Adrian, Thomas O'Hare
Publikováno v:
Blood. 114:3459-3463
Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e13cffee795cde588bec705619a0e01b
https://doi.org/10.1182/blood-2007-10-113969
https://doi.org/10.1182/blood-2007-10-113969
Autor:
Kurt W. Vogel, Dennis R. Koop, Lauren T. Adrian, Dorian LaTocha, Ryan MacKenzie, Brian J. Druker, Huihong You, Thomas O'Hare, Jeffrey W. Tyner, Jenny Luo, Bryan D. Marks, Matthew S. Zabriskie, Kara Johnson, Anupriya Agarwal, Steven M. Riddle, Christopher A. Eide, John Apgar, Michael W. Deininger
The imatinib paradigm in chronic myelogenous leukemia (CML) established continuous BCR-ABL inhibition as a design principle for ABL tyrosine kinase inhibitors (TKI). However, clinical responses seen in patients treated with the ABL TKI dasatinib desp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b35458dd3e7d2c4be9b2f453e74d7d
https://europepmc.org/articles/PMC3674150/
https://europepmc.org/articles/PMC3674150/
Autor:
Ira L. Kraft, Mary Alikian, Thoralf Lange, Michael W. Deininger, Philippe Szankasi, Lauren T. Adrian, Jamshid S. Khorashad, Thomas O'Hare, Matthew S. Zabriskie, Simona Soverini, Anna M. Eiring, David Marin, Todd W. Kelley, Letizia Foroni, Christopher A. Eide, Clinton C. Mason, Alistair Reid, Brian J. Druker, Anthony D. Pomicter, Zhimin Gu, Johanna Estrada, David J. Anderson
BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to cer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21b0911cc60ed52b81cb50b4dd326979
https://europepmc.org/articles/PMC3548169/
https://europepmc.org/articles/PMC3548169/
Autor:
Brian J. Druker, Dennis R. Koop, Anupriya Agarwal, Ryan MacKenzie, Steven M. Riddle, John R Apgar, Lauren T. Adrian, Thomas O'Hare, Matthew S. Zabriskie, Dorian LaTocha, Huihong You, Jenny Luo, Michael W. Deininger, Bryan D. Marks, Christopher A. Eide
Publikováno v:
Blood. 118:3504-3504
Abstract 3504 The imatinib paradigm established continuous BCR-ABL inhibition as a design principle for ABL tyrosine kinase inhibitors (TKIs). However, once-daily dasatinib (serum half-life: 3–5 h) is clinically effective despite only transient BCR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1efdf83b79f7818f306ffcc2009a0a9
https://doi.org/10.1182/blood.v118.21.3504.3504
https://doi.org/10.1182/blood.v118.21.3504.3504